Evaluation of the systemic oxidative stress status upon in vivo exposure to tramadol and tapentadol

Authors

  • C. Cardoso TOXRUN – Toxicology Research Unit, University Institute of Health Sciences–CESPU (IUCS-CESPU), 4585-116 Gandra, PRD, Portugal
  • R. J. Dinis-Oliveira TOXRUN – Toxicology Research Unit, University Institute of Health Sciences–CESPU (IUCS-CESPU), 4585-116 Gandra, PRD, Portugal; UCIBIO-REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal; Department of Public Health and Forensic Sciences, and Medical Education, Faculty of Medicine, University of Porto, 4099-002 Porto, Portugal; MTG Research and Development Lab, 4200-604 Porto, Portugal
  • S. Leal TOXRUN – Toxicology Research Unit, University Institute of Health Sciences–CESPU (IUCS-CESPU), 4585-116 Gandra, PRD, Portugal; CINTESIS@RISE, Department of Community Medicine, Information and Health Decision Sci-ences, Faculty of Medicine, University of Porto, 4099-002 Porto, Portugal
  • J. Barbosa TOXRUN – Toxicology Research Unit, University Institute of Health Sciences–CESPU (IUCS-CESPU), 4585-116 Gandra, PRD, Portugal; UCIBIO-REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
  • J. Faria TOXRUN – Toxicology Research Unit, University Institute of Health Sciences–CESPU (IUCS-CESPU), 4585-116 Gandra, PRD, Portugal; UCIBIO-REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal

DOI:

https://doi.org/10.48797/sl.2023.99

Keywords:

Poster

Abstract

Background: Tramadol and tapentadol are synthetic centrally acting analgesic opioids, used in the treatment of moderate to severe pain [1]. Despite their optimized therapeutic and safety profiles, these compounds are associated with adverse effects, namely CNS and respiratory depression, abuse and dependence [2, 3]. Oxidative stress is one of the main toxicity mechanisms triggered by opioids [1, 4, 5]. Objective: The aim of this study was to evaluate putative systemic oxidative stress changes induced by a therapeutic dose of tramadol and tapentadol. Methods: Three groups of Wistar rats (9 animals each) were administered intraperitoneally with 50 mg/kg tramadol/tapentadol during 8 alternate days, while the control group was treated with saline solution [1]. Serum total antioxidant capacity and ROS/RNS levels were determined through spectrophotometry, whilst serum cysteine and homocysteine levels were quantified through ELISA, with commercial kits, according to the manufacturers’ instructions. Statistical data analysis was performed through an Analysis of Variance (ANOVA), followed by Dunnett’s multiple comparison’s test. Results: An increase in ROS/RNS levels was observed in tramadol (*p<0.05) and tapentadol (***p<0.001) groups. However, regarding the antioxidant concentration, no significant differences were found. A statistically significant decrease in the concentration of cysteine was observed in the tramadol-administered group (*p<0.05). Furthermore, a statistically significant increase in the concentration of homocysteine was evident in the tapentadol-administered group (*p<0.05). Conclusions: The increase in ROS/RNS levels demonstrates that tramadol and tapentadol cause oxidative stress, with no changes in the total antioxidant capacity. However, as cysteine may have an antioxidant effect, the decrease in its serum levels may indicate that tramadol affects the levels of adjuvant antioxidants [6]. Since high levels of homocysteine causes oxidative stress, the increase in its serum concentration indicates that tapentadol induces oxidative stress [7]. In conclusion, tramadol and tapentadol must have a controlled prescription given their potential oxidative toxicity.

References

1. Barbosa, J., et al., Tramadol and Tapentadol Induce Conditioned Place Preference with a Differential Impact on Rewarding Memory and Incubation of Craving. Pharmaceuticals (Basel), 2023. 16(1).

2. Beakley, B.D., A.M. Kaye, and A.D. Kaye, Tramadol, Pharmacology, Side Effects, and Serotonin Syndrome: A Review. Pain Physician, 2015. 18(4): p. 395-400.

3. Polati, E., et al., Tapentadol: an overview of the safety profile. J Pain Res, 2019. 12: p. 1569-1576.

4. Ali, H.A., et al., Neurotoxic, Hepatotoxic and Nephrotoxic Effects of Tramadol Administration in Rats. J Mol Neurosci, 2020. 70(12): p. 1934-1942.

5. Faria, J., et al., Comparative study of the neurotoxicological effects of tramadol and tapentadol in SH-SY5Y cells. Toxicology, 2016. 359-360: p. 1-10.

6. Chiang, F.F., et al., Cysteine Regulates Oxidative Stress and Glutathione-Related Antioxidative Capacity before and after Colorectal Tumor Resection. Int J Mol Sci, 2022. 23(17).

7. Perna, A.F., D. Ingrosso, and N.G. De Santo, Homocysteine and oxidative stress. Amino Acids, 2003. 25(3-4): p. 409-17.

Downloads

Published

2023-04-21

How to Cite

Cardoso, C., Dinis-Oliveira, R. J., Leal, S., Barbosa, J., & Faria, J. (2023). Evaluation of the systemic oxidative stress status upon in vivo exposure to tramadol and tapentadol. Scientific Letters, 1(Sup 1). https://doi.org/10.48797/sl.2023.99

Issue

Section

Posters

Similar Articles

<< < 11 12 13 14 15 16 

You may also start an advanced similarity search for this article.